Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to...
Abivax starts enrolment in Phase IIb ulcerative colitis study
Abivax has recruited the first patient for a Phase IIb clinical trial assessing oral, once-daily ABX464 to treat moderate to severe active ulcerative colitis (UC).
Mallinckrodt’s terlipressin shows positive profile in CONFIRM study
Mallinckrodt has reported positive data from the Phase III CONFIRM trial of terlipressin conducted in hepatorenal syndrome type 1 (HRS-1) patients.
Alkermes-Biogen’s MS drug shows improved GI tolerability
Alkermes and Biogen have reported that diroximel fumarate demonstrated a statistically superior gastrointestinal (GI) tolerability profile compared to Tecfidera (dimethyl fumarate) in a Phase III EVOLVE-MS-2 study for relapsing-remitting multiple sclerosis (RRMS).
Takeda’s study of subcutaneous vedolizumab meets primary goal
Takeda Pharmaceutical has reported that the VISIBLE 2 clinical trial of a subcutaneous (SC) formulation of vedolizumab met its primary endpoint in adults with moderately to severely active Crohn's disease (CD).
Expert Insights: Amgen vs Sandoz Trial on Enbrel Biosimilar Delayed – How Long will Infliximab Biosimilars Dominate the US Anti-TNF Market?
Alexandra Annis, MS, Senior Immunology Analyst, GlobalData, assess what impact Sandoz’s delayed trial will have on the biosimilars market
Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease
Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.
Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)
Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).
Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease
Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease.
Viberzi (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D)
Viberzi (eluxadoline), an oral tablet developed by Actavis, is indicated for the treatment of adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).
Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease
Entyvio (vedolizumab) is a human monoclonal antibody indicated for treating adult patients with moderate to severe ulcerative colitis (UC) and those with moderate to severe Crohn's disease (CD).